

## RECORDATI: PUBLICATION OF DOCUMENTS

Milan, 13<sup>th</sup> May 2024 – Please be informed that **the Interim Report at 31<sup>st</sup> March 2024**, representing additional voluntary financial reporting, approved by the Board of Directors on 9<sup>th</sup> May 2024, as per the press release issued on the same date, today has been made available to the public at the Company's registered office, on the [Company's website](#) and on the "[1INFO](#)" storage mechanism.

Please also be informed that, pursuant to Article 125-quater of the Legislative Decree 58/98, **the minutes of the Ordinary General Meeting of the Shareholders** held on 22<sup>nd</sup> April 2024 have been made available today to the public at the Company's registered office, on the [Company's website](#) and on the "[1INFO](#)" storage mechanism.

**Recordati** (Reuters RECI.MI, Bloomberg REC IM) is an international pharmaceutical group listed on the Italian Stock Exchange (ISIN IT 0003828271) uniquely structured to bring treatment across specialty and primary care, consumer healthcare, and rare diseases. We believe that health, and the opportunity to live life to the fullest, is a right, not a privilege. We want to support people in unlocking the full potential of their lives. We have fully integrated operations across research & development, chemical and finished product manufacturing through to commercialisation and licensing. Established in 1926, Recordati operates in approximately 150 countries across EMEA, Americas and APAC regions. At the end of 2023, Recordati employed over 4,450 people and consolidated revenue of € 2,082.3 million. For more information, please visit [www.recordati.com](http://www.recordati.com)

### Investor Relations

Eugenia Litz  
+44 7824 394 750  
[investorelations@recordati.it](mailto:investorelations@recordati.it)

### Investor Relations

Lucia Abbatantuoni  
+39 337 1025645  
[investorelations@recordati.it](mailto:investorelations@recordati.it)

### Media Relations Brunswick:

Barbara Scalchi / Andrea Mormandi  
+39 02 9288 6200  
[recordati@brunswickgroup.com](mailto:recordati@brunswickgroup.com)

### RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.p.A.

Registered office  
VIA M. CIVITALI, 1  
20148 MILAN, ITALY  
TEL. +39 0248787.1  
FAX +39 0240073747

SHARE CAPITAL € 26,140,644.50 fully paid up  
BUSINESS REGISTER OF MILAN, MONZA, BRIANZA and LODI  
00748210150  
TAX CODE/VAT NO. 00748210150

Company subject to management and coordination by Rossini Luxembourg S.à.r.l